Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
3.800
+0.070 (1.88%)
Dec 20, 2024, 4:00 PM EST - Market closed
Marker Therapeutics Employees
Marker Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 59 or -88.06% compared to the previous year.
Employees
8
Change (1Y)
-59
Growth (1Y)
-88.06%
Revenue / Employee
$674,481
Profits / Employee
-$1,212,095
Market Cap
33.91M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
NeueHealth | 1,252 |
Precision Optics Corporation | 85 |
Actinium Pharmaceuticals | 49 |
Movano | 30 |
Outlook Therapeutics | 24 |
Lantern Pharma | 21 |
NEXGEL | 19 |
VYNE Therapeutics | 10 |
MRKR News
- 2 days ago - Marker Therapeutics Announces $16.1 Million Private Placement - GlobeNewsWire
- 2 days ago - Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - GlobeNewsWire
- 4 days ago - Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer - GlobeNewsWire
- 11 days ago - Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium - GlobeNewsWire
- 25 days ago - Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit - GlobeNewsWire
- 5 weeks ago - Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma - GlobeNewsWire